Attention-deficit hyperactivity disorder

Alternative and Complementary Therapies

Volumn 14, Issue 5, 2008, Pages 235-242

  Meletis, Chris D ^a,b   Zabriskie, Nieske ^c  

^a Institute for Healthy Aging   (United States)

^b National College of Natural Medicine   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 54349125349     PISSN: 10762809     EISSN: None     Source Type: Journal    
DOI: 10.1089/act.2008.14501     Document Type: Review

References (61)

1. Centers for Disease Control and Prevention (CDC). CDC Fastats: Attention Deficit Disorder with Hyperactivity. Online document at: www.cdc.gov/nchs/ fastats/adhd.htm. Accessed July 15, 2008.
2. Bauermeister JJ, Shrout PE, Chávez L, et al. ADHD and gender: Are risks and sequela of ADHD the same for boys and girls? J Child Psychol Psychiatry 2007;48:831-839.
3. Kessler RC, Adler L, Barkley R, et al. The prevalence and correlates of adult ADHD in the United States: Results from the National Comorbidity Survey Replication. Am J Psychiatry 2006;163:716-723.
4. Centers for Disease Control and Prevention. Attention Deficit/Hyperactivity Disorder (ADHD): Report on the Prevalence of Diagnosed and Medicated Attention-Deficit/Hyperactivity Disorder: United States, 2003. Online document at: www.cdc.gov/ncbddd/adhd/default.htm Accessed July 15, 2008.
5. Sinha D, Efron D. Complementary and alternative medicine use in children with attention deficit hyperactivity disorder. J Paediatr Child Health 2005;41:23-26.
6. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th ed., text rev. Washington, DC: American Psychiatric Association, 2000.
7. Centers for Disease Control and Prevention. What Is Attention Deficit/Hyperactivity Disorder (ADHD)? Online document at: www.cdc.gov/ncb-ddd/ adhd/what.htm Accessed July 15, 2008.
8. Sung V, Hiscock H, Sciberras E, et al. Sleep problems in children with attention-deficit/hyperactivity disorder: Prevalence and the effect on the child and family. Arch Pediatr Adolesc Med 2008;162:336-342.
9. Centers for Disease Control and Prevention. Attention Deficit/Hyperactivity Disorder (ADHD): ADHD and Risk of Injuries. Online document at: www.cdc.gov/ncbddd/adhd/injury.htm Accessed July 15, 2008.
10. Faraone SV, Wilens TE. Effect of stimulant medications for attention-deficit/hyperactivity disorder on later substance use and the potential for stimulant misuse, abuse, and diversion. J Clin Psychiatry 2007;68(suppl11):15-22.
11. Faraone SV, Biederman J. Neurobiology of attention-deficit hyperactivity disorder. Biol Psychiatry 1998;44:951-958.
12. Waldman ID, Gizer IR. The genetics of attention deficit hyperactivity disorder. Clin Psychol Rev 2006;26:396-432.
13. Biederman J, Faraone SV, Keenan K, et al. Family-genetic and psychosocial risk factors in DSM-III attention deficit disorder. J Am Acad Child Adolesc Psychiatry 1990;29:526-533.
14. Banerjee TD, Middleton F, Faraone SV. Environmental risk factors for attention-deficit hyperactivity disorder. Acta Paediatr 2007;96:1269-1274.
15. Thapar A, Langley K, Owen MJ, et al. Advances in genetic findings on attention deficit hyperactivity disorder. Psychol Med 2007;37:1681-1692.
16. Retz W, Rösler M, Kissling C, et al. Norepinephrine transporter and catecholamine-O-methyltransferase gene variants and attention-deficit/ hyperactivity disorder symptoms in adults. J Neural Transm 2008;115:323-329.
17. Durston S, Fossella JA, Mulder MJ, et al. Dopamine transporter genotype conveys familial risk of attention-deficit/hyperactivity disorder through striatal activation. J Am Acad Child Adolesc Psychiatry 2008;47:61-67.
18. Castellanos FX, Lee PP, Sharp W, et al. Developmental trajectories of brain volume abnormalities in children and adolescents with attention-deficit/ hyperactivity disorder. JAMA 2002;288:1740-1748.
19. Perlov E, Philipsen A, Hesslinger B, et al. Reduced cingulate glutamate/glutamine-to-creatine ratios in adult patients with attention deficit/hyperactivity disorder - a magnet[sic] resonance spectroscopy study. J Psychiatr Res 2007;41:934-941.
20. Carrey NJ, MacMaster FP, Gaudet L, et al. Striatal creatine and glutamate/glutamine in attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2007;17:11-17.
21. Schnoll R, Burshteyn D, Cea-Aravena J. Nutrition in the treatment of attention-deficit hyperactivity disorder: A neglected but important aspect. Appl Psychophysiol Biofeedback 2003;28:63-75.
22. National Institutes of Health. Defined Diets and Childhood Hyperactivity. National Institutes of Health Consensus Development Statement,1982; 4:1-11. Online document at: http://consensus.nih.gov/1982/1982DietHyperactivity032html. htm Accessed September 9, 2008.
23. Rowe KS, Rowe KJ. Synthetic food coloring and behavior: A dose response effect in a double-blind, placebo-controlled, repeated-measures study. J Pediatr 1994;125:691-698.
24. Rowe KS. Synthetic food colorings and "hyperactivity": A double-blind crossover study. Aust Paediatr J 1988;24:143-147.
25. Pineda DA, Palacio LG, Puerta IC, et al. Environmental influences that affect attention deficit/hyperactivity disorder: Study of a genetic isolate. Eur Child Adolesc Psychiatry 2007 Aug;16:337-346.
26. Braun JM, Kahn RS, Froehlich T, et al. Exposures to environmental toxicants and attention deficit hyperactivity disorder in U.S. children. Environ Health Perspect 2006;114:1904-1909.
27. McNamara RK, Carlson SE. Role of omega-3 fatty acids in brain development and function: Potential implications for the pathogenesis and prevention of psychopathology. Prostaglandins Leukot Essent Fatty Acids 2006;75:329-349.
28. Kadziela-Olech H, Piotrowska-Jastrzebska J. The duration of breastfeeding and attention deficit hyperactivity disorder. Rocz Akad Med Bialymst 2005;50:302-306.
29. Hultman CM, Torrång A, Tuvblad C, et al. Birth weight and attention-deficit/hyperactivity symptoms in childhood and early adolescence: A prospective Swedish twin study. J Am Acad Child Adolesc Psychiatry 2007;46:370-377.
30. Tran TT, Chowanadisai W, Lönnerdal B, et al. Effects of neonatal dietary manganese exposure on brain dopamine levels and neurocognitive functions. Neurotoxicology 2002;23:645-651.
31. Bouchard M, Laforest F, Vandelac L, et al. Hair manganese and hyperactive behaviors: Pilot study of school-age children exposed through tap water. Environ Health Perspect 2007;115:122-127.
32. Builee TL, Hatherill JR. The role of polyhalogenated aromatic hydrocarbons on thyroid hormone disruption and cognitive function: A review. Drug Chem Toxicol 2004;27:405-424.
33. Negishi T, Kawasaki K, Sekiguchi S, et al. Attention-deficit and hyperactive neurobehavioural characteristics induced by perinatal hypothyroidism in rats. Behav Brain Res 2005;159:323-331.
34. Vermiglio F, Lo Presti VP, Moleti M, et al. Attention deficit and hyperactivity disorders in the offspring of mothers exposed to mild-moderate iodine deficiency: A possible novel iodine deficiency disorder in developed countries. J Clin Endocrinol Metab 2004;89:6054-6060.
35. National Institute of Mental Health. The Treatment of ADHD. Online document at: www.nimh.nih.gov/health/publications/adhd/treatment.shtml Accessed July 15, 2008.
36. The MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention-deficit hyperactivity disorder (ADHD). Arch Gen Psychiatry 1999;56:1073-1086.
37. Wilens TC, Faraone, SV, Biederman J, et al. Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature. Pediatrics 2003;111:179-185.
38. Vancassel S, Blondeau C, Lallemand S, et al. Hyperactivity in the rat is associated with spontaneous low level of n-3 polyunsaturated fatty acids in the frontal cortex. Behav Brain Res 2007;180:119-126.
39. Colter AL, Cutler C, Meckling KA. Fatty acid status and behavioural symptoms of attention deficit hyperactivity disorder in adolescents: A case-control study. Nutr J 2008;7:8.
40. Ross BM, McKenzie I, Glen I, et al. Increased levels of ethane, a noninvasive marker of n-3 fatty acid oxidation, in breath of children with attention deficit hyperactivity disorder. Nutr Neurosci 2003;6:277-281.
41. Sorgi PJ, Hallowell EM, Hutchins HL, et al. Effects of an open-label pilot study with high-dose EPA/DHA concentrates on plasma phospholipids and behavior in children with attention deficit hyperactivity disorder. Nutr J 2007;6:16.
42. Young GS, Maharaj NJ, Conquer JA. Blood phospholipid fatty acid analysis of adults with and without attention deficit/hyperactivity disorder. Lipids 2004;39:117-123.
43. Sinn N, Bryan J. Effect of supplementation with polyunsaturated fatty acids and micronutrients on learning and behavior problems associated with child ADHD. J Dev Behav Pediatr 2007;28:82-91.
44. Pelsser LM, Buitelaar JK. Favourable effect of a standard elimination diet on the behavior of young children with attention deficit hyperactivity disorder (ADHD): A pilot study. Ned Tijdschr Geneeskd 2002;146:2543-2547.
45. Boris M, Mandel FS. Foods and additives are common causes of the attention deficit hyperactive disorder in children. Ann Allergy 1994;72:462-468.
46. Carter CM, Urbanowicz M, Hemsley R, et al. Effects of a few food diet in attention deficit disorder. Arch Dis Child 1993;69:564-568.
47. Pelsser LM, Frankena K, Toorman J, et al. A randomised controlled trial into the effects of food on ADHD. Eur Child Adolesc Psychiatry 2008 Apr 21;e-pub ahead of print.
48. Salamy J, Shucard D, Alexander H, et al. Physiological changes in hyperactive children following the ingestion of food additives. Int J Neurosci 1982;16:241-246.
49. Kozielec T, Starobrat-Hermelin B. Assessment of magnesium levels in children with attention deficit hyperactivity disorder (ADHD). Magnes Res 1997;10:143-148.
50. Starobrat-Hermelin B, Kozielec T. The effects of magnesium physiological supplementation on hyperactivity in children with attention deficit hyperactivity disorder (ADHD): Positive response to magnesium oral loading test. Magnes Res 1997;10:149-156.
51. 6: I. Attention deficit hyperactivity disorders. Magnes Res 2006;19:46-52.
52. Coleman M, Steinberg G, Tippett J, et al. A preliminary study of the effect of pyridoxine administration in a subgroup of hyperkinetic children: A double-blind crossover comparison with methylphenidate. Biol Psychiatry 1979 Oct;14:741-751.
53. Bhagavan HN, Coleman M, Coursin DB. The effect of pyridoxine hydrochloride on blood serotonin and pyridoxal phosphate contents in hyperactive children. Pediatrics 1975;55:437-441.
54. Arnold LE, DiSilvestro RA. Zinc in attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2005;15:619-627.
55. Arnold LE, Bozzolo H, Hollway J, et al. Serum zinc correlates with parent-and teacher-rated inattention in children with attention-deficit/ hyperactivity disorder. J Child Adolesc Psychopharmacol 2005;15:628-636.
56. Bilici M, Yildirim F, Kandil S, et al. Double-blind, placebo-controlled study of zinc sulfate in the treatment of attention deficit hyperactivity disorder. Prog Neuropsychopharmacol Biol Psychiatry 2004;28:181-190.
57. Konofal E, Lecendreux M, Deron J, et al. Effects of iron supplementation on attention deficit hyperactivity disorder in children. Pediatr Neurol 2008;38:20-26.
58. Konofal E, Cortese S. Lead and neuroprotection by iron in ADHD. Environ Health Perspect 2007;115:A398-A399.
59. David OJ, Hoffman SP, Sverd J, et al. Lead and hyperactivity: Behavioral response to chelation. A pilot study. Am J Psychiatry 1976;133:1155-1158.
60. Van Oudheusden LJ, Scholte HR. Efficacy of carnitine in the treatment of children with attention-deficit hyperactivity disorder. Prostaglandins Leukot Essent Fatty Acids 2002;67:33-38.
61. Chen JR, Hsu SF, Hsu CD, et al. Dietary patterns and blood fatty acid composition in children with attention-deficit hyperactivity disorder in Taiwan. J Nutr Biochem 2004;15:467-472.